NICE Rejects Pierre Fabre’s Javlor, Citing Basic Evidence Errors
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE has turned down Pierre Fabre’s Javlor for cancer of the urothelial tract, saying the French company’s basic trial structure did not meet its requirements.
You may also be interested in...
Javlor Falls Short Again At NICE; Even Sole Treatment In Class Faces Cost Hurdle
NICE questions the cost and clinical effectiveness Pierre Fabre’s Javlor for metastatic transitional cell carcinoma in a disappointing final appraisal for the drug.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.